Daniel J Lodge Selected Research

Psychotic Disorders (Schizoaffective Disorder)

2/2024	Extrasynaptic localization is essential for α5GABAA receptor modulation of dopamine system function.
7/2023	α5-GABAA Receptor Modulation Reverses Behavioral and Neurophysiological Correlates of Psychosis in Rats with Ventral Hippocampal Alzheimer's Disease-like Pathology.
7/2023	GL-II-73, a Positive Allosteric Modulator of α5GABAA Receptors, Reverses Dopamine System Dysfunction Associated with Pilocarpine-Induced Temporal Lobe Epilepsy.
7/2023	Extrasynaptic localization is essential for α5GABA A receptor modulation of dopamine system function.
4/2023	Aberrant Dopamine System Function in the Ferrous Amyloid Buthionine (FAB) Rat Model of Alzheimer's Disease.
1/2021	Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis.
1/2021	Orexin Modulation of VTA Dopamine Neuron Activity: Relevance to Schizophrenia.
1/2019	Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat.
12/2018	Convergent Inputs from the Hippocampus and Thalamus to the Nucleus Accumbens Regulate Dopamine Neuron Activity.
1/2018	Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel J Lodge Research Topics

Disease

34	Schizophrenia (Dementia Praecox) 03/2024 - 07/2006
17	Psychotic Disorders (Schizoaffective Disorder) 02/2024 - 10/2007
3	Shock 02/2024 - 09/2015
3	Opioid-Related Disorders (Opiate Addiction) 07/2022 - 01/2022
3	Mental Disorders (Mental Disorder) 07/2022 - 05/2011
3	Substance-Related Disorders (Drug Abuse) 01/2022 - 05/2007
2	Neonatal Abstinence Syndrome 07/2022 - 01/2022
2	Pain (Aches) 01/2022 - 01/2022
1	Seizures (Absence Seizure) 07/2023
1	Temporal Lobe Epilepsy 07/2023
1	Alzheimer Disease (Alzheimer's Disease) 04/2023
1	Blindness (Hysterical Blindness) 01/2023
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2021
1	Hallucinations (Hallucination) 01/2020
1	Neurodevelopmental Disorders 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2020
1	Autistic Disorder (Autism) 01/2018
1	AIDS-Related Complex (ARC) 05/2017
1	Neurobehavioral Manifestations 05/2017
1	Cognitive Dysfunction 05/2017
1	Treatment-Resistant Depressive Disorder 07/2014
1	Epilepsy (Aura) 07/2014
1	Dyskinesias (Dyskinesia) 08/2010
1	Parkinson Disease (Parkinson's Disease) 08/2010

Drug/Important Bio-Agent (IBA)

29	Dopamine (Intropin)FDA LinkGeneric 02/2024 - 07/2006
16	Methylazoxymethanol AcetateIBA 01/2023 - 10/2008
7	Antipsychotic Agents (Antipsychotics)IBA 07/2023 - 11/2012
5	ParvalbuminsIBA 03/2024 - 02/2009
4	Amphetamine (Amfetamine)FDA LinkGeneric 01/2017 - 10/2007
3	gamma-Aminobutyric Acid (GABA)IBA 02/2024 - 01/2014
3	Opioid Analgesics (Opioids)IBA 07/2022 - 01/2022
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2017
3	CannabinoidsIBA 01/2018 - 10/2014
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 03/2024 - 10/2019
2	Neurotransmitter Agents (Neurotransmitter)IBA 03/2024 - 01/2018
2	Buprenorphine (Subutex)FDA LinkGeneric 07/2022 - 01/2022
2	Orexin ReceptorsIBA 01/2021 - 01/2021
2	OrexinsIBA 01/2021 - 01/2021
2	Ketamine FDA LinkGeneric 01/2020 - 05/2017
2	Poly I-CIBA 01/2020 - 01/2018
2	EndocannabinoidsIBA 02/2016 - 10/2014
2	Dronabinol (THC)FDA LinkGeneric 02/2016 - 10/2014
1	Calcium-Binding ProteinsIBA 03/2024
1	Anticonvulsants (Antiepileptic Drugs)IBA 07/2023
1	Pilocarpine (Ocusert)FDA LinkGeneric 07/2023
1	GABA-A Receptors (GABA(A) Receptor)IBA 07/2023
1	Amyloid (Amyloid Fibrils)IBA 04/2023
1	buthionineIBA 04/2023
1	Dizocilpine Maleate (Dizocilpine)IBA 04/2023
1	nasIBA 07/2022
1	Narcotic Antagonists (Opioid Antagonists)IBA 07/2022
1	Oxycodone (Oxycontin)FDA LinkGeneric 07/2022
1	Opioid Receptors (Opioid Receptor)IBA 07/2022
1	Dihydroxyphenylalanine (Dopa)IBA 01/2022
1	Drug CombinationsIBA 01/2022
1	suvorexantIBA 01/2021
1	Orexin Receptor AntagonistsIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2020
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Antidepressive Agents (Antidepressants)IBA 05/2017
1	Therapeutic UsesIBA 05/2017
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 02/2016
1	Phencyclidine (Angel Dust)IBA 02/2016
1	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 02/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	N- succinimidyl- 3- (2- pyridyldithio)butyrateIBA 09/2015
1	anandamide (arachidonylethanolamide)IBA 10/2014
1	Acetates (Acetic Acid Esters)FDA Link 07/2014
1	Glutamic Acid (Glutamate)FDA Link 01/2014
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 11/2012
1	Chloral HydrateIBA 02/2012
1	Dopamine Agonists (Dopamine Agonist)IBA 05/2011
1	Levodopa (L Dopa)FDA LinkGeneric 08/2010

Therapy/Procedure

6	Therapeutics 04/2023 - 05/2011
1	Precision Medicine 01/2020
1	Vagus Nerve Stimulation 07/2014
1	Deep Brain Stimulation 07/2013